Calliditas is a commercial stage biopharmaceutical company focused on novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. In 2021, Calliditas acquired Genkyotex, specializing company in NOX therapies, French & Swiss based.
- https://www.calliditas.se/en/
- +41 22 880 10 25
- info.ch@calliditas.com
